BCR-ABL inhibitor ELVN-001

{
  "id": "MLC-T-ONC-011920",
  "term": "BCR-ABL inhibitor ELVN-001",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, selective, active-form inhibitor of tyrosine kinase BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL inhibitor ELVN-001 specifically targets and binds to the ATP-binding site in the kinase domain of activated BCR-ABL1, thereby inhibiting the activity of both wild-type BCR-ABL and certain mutation forms, including the T315I mutation. This binding results in the inhibition of BCR-ABL-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The BCR-ABL fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome. The T315I mutation, the most common BCR-ABL mutation, shows resistance to nearly all commonly used tyrosine kinase inhibitors (TKIs).",
  "synonyms": [
    "BCR-ABL TKI ELVN-001",
    "BCR-ABL tyrosine kinase inhibitor ELVN-001"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bcr-abl-inhibitor-elvn-001/"
}